Lv41
468 积分 2021-01-06 加入
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study
2小时前
待确认
Management of T‐cell malignancies: Bench‐to‐bedside targeting of epigenetic biology
4个月前
已完结
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase 1b/2 dose-escalation and dose-expansion study
4个月前
已完结
Sunvozertinib monotherapy in EGFR tyrosine kinase Inhibitor-Resistant Non-Small cell lung cancer with EGFR mutations
5个月前
已完结
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial
8个月前
已完结
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
8个月前
已完结
OA02.06 PSM Analysis Results from REFRACT: A Multi-Center Cohort Study Investigating the Treatment Patterns in EGFR-Mutant Unresectable LA- NSCLC
9个月前
已完结
Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial
9个月前
已完结
A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non–small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L)
9个月前
已完结
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
9个月前
已完结
皖公网安备34019202002308
